Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Storz & Bickel gross margin was 51% compared to 45% last year, in part due to lower input costs and a positive mix shift with Venty, carrying higher gross margin than the rest of the portfolio |
| Our Australian team delivered its 12th consecutive quarter of record revenue |
| Our businesses are growing and demonstrating healthy margins and Canopy USA is moving forward |
| Completion of our Q3, marks the dawn of a new era for Canopy, we’re immensely proud of where we are today and feel strongly that Canopy is positioned for lasting leadership |
| But even in Europe, we are also seeing the margin improvement there as well |
| The one thing to call out from an Australian business standpoint, in our Australian business, we also have Storz & Bickel sales that go through just from a reported segments standpoint, to the Australia sales as part of the rest of the world sales, and that Storz & Bickel business, frankly, has really grown strongly in Australia |
| By focusing exclusively on cannabis and right sizing our footprint, we strengthen our path to delivering sustainable operating profit, and ensure we are well positioned to capitalize on what we feel is the greatest consumer trend of our lifestyle |
| And we're also actually seeing margin improvement in that part of the business with some of the product mix improvements that we're seeing in that platform as well |
| To summarize, we've cut Canopy to size and are now delivering on improved gross margins, enhanced commercial execution, and are focused on demonstrating growth across all of our business units |
| This has enabled us to significantly improve our overall gross margins, with Q3 marking the second quarter in a row of margins in the mid-30s at the total company level |
| From this strength in base, we're generating growth backed by enhanced execution and consistent high quality products |
| In summary, we believe canopy offers shareholders a unique opportunity to gain exposure to arguably the most exciting consumer product trend of our time into the fastest growing cannabis markets in the world |
| So I think the combination of really strong growth in the flower business in Australia, as well as growing business in Storz & Bickel |
| There are several contributors to this growth, but at the core, we're continuing to deliver a great flower and it's been very well received by provincial cannabis boards, retailers, and most importantly consumers, not to mention our staff |
| But now the improvement we're seeing in markets like Germany, give us confidence that the margins that we're seeing today should be sustainable going forward |
| So product categories where it's more profitable, we're really leaning in there with better margins |
| And obviously, we are also seeing that in our P&L to some extent, but we're definitely seeing gross margin improvement, in part because we're shifting our mix |
| which is an extremely attractive and profitable cannabis market |
| We've also developed a robust new product introduction cycle to win market share across priority categories, including pre-rolled, vapes and soft gels |
| In pre-rolled, we're going to continue our record of success by launching new large packs, infused pre-rolls and burners over the coming months |
| In addition, we have an exciting lineup of Tweed and 7ACRES vape products coming to market with differentiated flavor profiles, and we expect to truly delight consumers as we step firmly back into the vape category |
| So, I think that continues to show the evidence that we're really leaning in a profitable growth |
| We had some of that lingering benefit in Q3, so that helped Q3 gross margin performance in the Canadian business, a little bit better than we anticipated at that point in time as well |
| And we feel Canopy is well positioned to achieve categorical leadership |
| So really the benefits of Canopy USA creating value by owning an operating platform once they're able to exercise the options and trigger on owning one Acreage, the value creation at Canopy USA, we think it’s really an attractive proposition for Canopy growth shareholders as well |
| In closing, we believe our Q3 results reinforce our confidence, but we now have a solid foundation in place to achieve profitability and drive profitable growth and enhance shareholder value over time |
| Following the series of balance sheet actions, we've completed over the past year, we have significantly strengthened our financial position |
| We're especially proud of our medical team as they continue to drive ongoing assortment expansion in the spectrum store, including a wide range of exclusive products all backed by exceptional patient service |
| This strategy has led to record revenues on a daily, weekly, monthly and quarterly basis, including in the third quarter |
| And importantly, these record revenues were achieved while improving markets |
| Statement |
|---|
| Sales on a year-over-year basis were impacted by reduced shipments to the U.S., due to continuous financial challenges faced by distributors |
| But the revenue was down 8% year-over-year, presumably that's with some pricing embedded into it |
| And that's caused us some, some pain over time |
| We also have historically had a bulk shipment to some of the markets outside North America and that also created volatility in the gross margin performance as well |
| But, yes, there's still some pressure in the marketplace |
| I would say that our results in Q3 were held back a little bit, by the late launch of Venty, which happened late in the quarter |
| I just wanted to get a little more commentary, if you can provide your overall outlook on sort of your Canadian domestic operations, clearly, we've seen a bit of softness to end the year, at least at the retail levels in Canada, and the overall medical opportunity seems to be flat to declining |
| Initial demand for Venty exceeded production, those sales were constraints early in the quarter as we added a second production shift to better align production with demand |
| Storz & Bickel revenue of $18 million in Q3 was up 54% sequentially, but down 9% year-over-year |
| And then there are some areas where, where we can't produce enough product to meet consumer demand |
| In fact, after our initial production run, we've had to add a second shift to further increase capacity and ensure availability matches the consumer demand, which shows no sign of slowing |
| So I think Michael, there's still price compression in some of the categories |
| CBD business and the changes there have impacted the gross margins, as well as the revenue in some of the quarters |
| I hit the wrong button |
| S&B Australia sales will also see some impact on the upcoming regulation changes on vapes |
| Does that mean consolidated, profitable or their unallocated expenses, maybe at the corporate level that would make consolidated EBITDA negative even if all business units were EBITDA positive? Judy Hong So, Bill, we don't break out segment information at the adjusted EBITDA level |
| And as you know, the U.S., China distribution tier, it has been under duress for the last couple of years that meaning the tier that takes products into vape shops across the United States |
Please consider a small donation if you think this website provides you with relevant information